Pivotal phase III study of hepatic arterial infusion of melphalan with venous filtration via peripheral hepatic perfusion for the treatment of hepatocellular carcinoma.

Trial Profile

Pivotal phase III study of hepatic arterial infusion of melphalan with venous filtration via peripheral hepatic perfusion for the treatment of hepatocellular carcinoma.

Planning
Phase of Trial: Phase III

Latest Information Update: 21 May 2013

At a glance

  • Drugs Melphalan (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Delcath Systems
  • Most Recent Events

    • 21 May 2013 Pending a decision from the FDA, Delcath anticipate that this trial will commence by the end of 2013, according to the Delcath Q1 20-13 financial report.
    • 25 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top